Bruker Corp. (NSDQ:BRKR) said today it inked a deal to pick up Oncovision‘s preclinical imaging business for an undisclosed amount. Oncovision will retain its clinical human imaging business, including its Mammi PET breast cancer diagnostic tool, the companies said. “With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The […]
Oncology
DelMar, Accurexa ink deal for chemotherapy combo
DelMar Pharmaceuticals and Accurexa said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable […]
Cardinal Health to pay up to $310m for Navidea’s LymphoSeek
Navidea (NYSE:NAVB) said today it inked a letter of intent with Cardinal Health (NYSE:CAH) to sell its Lymphoseek injection for up to $310 million. The sale includes all current FDA-approved indications, as well as future oncology diagnostic indications in North America and other related assets, Dublin, Ohio-based Navidea said. Through the deal, Navidea is slated to receive $80 […]
Novocure touts data from Optune-paclitaxel combination study
By Sarah Faulkner NovoCure (NSDQ:NVCR) announced yesterday that its ‘tumor treating fields, combined with the drug paclitaxel, are effective against ovarian cancer, the 5th most-common cause of cancer death in women in the US. The St. Helier, N.J.-based company won FDA approval in July for the Optune device to treat a type of brain cancer called glioblastoma. TTFields […]
Micrima brings in $3.4m for breast imaging tech
Micrima said today it raised $3.4 million (UK £2.6 million) in a new round of financing to support its Maria breast imaging system, with commercialization slated for the end of the year. Micrima’s Maria radiowave breast imaging system won CE Mark approval in the European Union in 2015, and the company said it is making “excellent […]
Scion Medical’s Medlink closes $4m Perseon buyout
Perseon Medical (NSDQ:PRSN) said yesterday that it closed the sale of its assets this week and reverted to its former name, BSD Medical, as part of the deal. The $4.35 million sale, which closed August 22, was part of the Chapter 11 bankruptcy proceedings for Perseon, which makes the MicroThermX microwave ablation system for treating soft tissue tumors. The device can […]
Sirtex Medical jumps on surging sales, profits for fiscal 2016
By Sarah Faulkner Shares in Sirtex Medical (ASX:SRX) closed up nearly 12% today after the Australian medical device company posted huge boosts to both the bottom and top lines. Sydney-based Sirtex Medical makes targeted liver cancer therapies using resin microspheres called SIR-sphere Y-90. Sirtex said profits were $40.8 million (A$53.6 million), or 70¢ (A92.2¢) per share, on sales of […]
Dune Medical lands $3.4m EU grant
Dune Medical Devices said today it won a $3.4 million (EU €3 million) European Union Horizon 2020 research grant. The company said it is 1 of 65 companies selected to receive funding from the $91 billion (EU €80 billion) 7-year program aiming to “secure Europe’s global competitiveness.” “This 3 million euro grant will expedite bringing our […]
FDA adds new clearance for Cianna Medical’s Savi Scout breast cancer locator
Cianna Medical said today it won additional FDA 510(k) clearance for its Savi Scout radar localization breast cancer device, now cleared to be placed at the lumpectomy site up to 30 days prior to surgical removal. Aliso Viejo, Calif.-based Cianna’s Savi Scout is designed to produce audible and visual indicators surgeons can use to tag […]
IBM Watson inks deal with 21 Chinese hospitals
IBM‘s (NYSE:IBM) Watson health group said today that inked a deal to supply 21 hospitals in China with its Watson for Oncology platform designed to assist in providing personalized, evidence-based cancer treatment options. The company said it is partnering with Hangzhou CognitiveCare to introduce more hospitals across China, and touted the partnership as Watson Health’s […]
Taris launches another Phase I trial for bladder cancer drug-device combo
Taris Biomedical said today it is launching a new phase I trial of its TAR-200 gemcitabine releasing intravesical system designed to deliver drugs directly to the bladder for patients with non-muscle-invasive bladder cancer. The phase 1b open-label study is slated to enroll 30 patients to explore whether continuous, local exposure to gemcitabine using TAR-200 is […]